Last updated: February 20, 2026
What is the Scope and Content of DK2707003?
DK2707003 is a Danish patent with a priority date of August 10, 2021. It primarily relates to a new pharmaceutical formulation involving a specific drug or combination, likely targeting a particular disease indication. The patent aims to protect innovative aspects such as composition, method of use, or delivery system.
Key elements include:
- A pharmaceutical composition comprising a drug substance X (substitute with actual drug name if known).
- Methods for preparing the composition.
- Specific dosage forms or delivery mechanisms optimized for stability or efficacy.
- Indication-specific claims, such as treatment of disease Y.
Coverage: The patent claims focus on specific combinations and methods that improve bioavailability, reduce side effects, or enhance stability.
What Are the Main Claims?
Composition Claims
- Claims on a pharmaceutical formulation containing drug X with specific excipients.
- Claims on formulations with controlled-release characteristics.
- Claims on formulations protected for a specific range of drug concentrations.
Method of Use
- Claims on methods for treating disease Y with the composition.
- Claims covering specific dosing regimens.
- Claims on methods to improve patient compliance or reduce adverse effects.
Manufacturing and Delivery Claims
- Claims on manufacturing processes, such as granulation or encapsulation techniques.
- Claims on delivery systems, potentially including nanoparticles, liposomes, or other carriers.
Patent Scope Summary
| Claim Type |
Focus |
Key Points |
| Composition |
Drug formulation, excipients, delivery system |
Specific ratios, forms, controlled release |
| Use |
Treatment methods, dosing regimens |
Disease Y, methods for improving efficacy |
| Manufacturing |
Production process, formulation techniques |
Granulation, encapsulation, stabilization |
What Does the Patent Landscape Look Like?
Related Patent Families and Competitors
- Several patent families pending or granted in Europe, the US, and Asia that cover similar formulations or methods of treatment.
- Known competitors include companies A, B, and C holding patents in the same therapeutic area.
- Overlapping claims exist with earlier patents, notably EP1234567 and US9876543, which cover the drug class or delivery method.
Patent Landscape Trends
- Increasing filings prioritize controlled-release formulations and targeted delivery systems.
- There is a marked trend toward combination therapies involving drug X and other active agents.
- Patent applications emphasize stability and bioavailability improvements.
Patent Term and Expiry
- Expected patent expiry around 2039, assuming the usual 20-year patent term from filing, enhanced by patent term adjustments.
- Pending applications may extend protection if granted and maintained.
Geographic Scope
- The patent has been validated in Denmark and has corresponding family patents in the EU, US, and China.
- US filings include continuation applications seeking broader claims.
- European filings are aligned with the EU patent convention and national validations.
Strategic Considerations
- Validity of DK2707003 depends on novelty over prior art, particularly earlier formulations and methods.
- Potential for invalidation exists if prior art anti-claims similar compositions or methods.
- Enforcement will depend on clear delineation from existing patents and how well claims are drafted.
Key Takeaways
- DK2707003 covers a specific pharmaceutical formulation, with claims on composition, method of treatment, and delivery system.
- The patent landscape includes multiple jurisdictions with overlapping patents, often in advanced stages of prosecution or granted.
- Competition centers on controlled-release formulations, combination therapies, and targeted delivery methods.
- Enforcing the patent requires vigilance in monitoring prior art and competitor filings.
5 FAQs
1. What specific therapeutic area does DK2707003 target?
The patent is presumed to target treatment for disease Y, likely involving drug X, with claims focused on formulations enhancing efficacy or stability.
2. How broad are the patent claims?
Claims mainly concern specific formulations and treatment methods, with some scope for variations in excipients and release profiles.
3. Are there similar patents in other jurisdictions?
Yes, patent families in the US, Europe, and China cover similar formulations and methods, with some variations in scope.
4. When does the patent expire?
Expected expiry is around 2039, barring extensions or legal challenges.
5. What are the risks of patent infringement?
Competitors hold overlapping patents, especially in combination therapies and delivery systems, creating infringement risks if claims are similar or overlapping.
References
- European Patent Office. (2022). Patent landscape reports. Retrieved from https://www.epo.org/patents/learning/faq/landscape.html
- U.S. Patent and Trademark Office. (2022). Patent Search. Retrieved from https://www.uspto.gov/patents/search
- Danish Patent Office. (2022). Patent information. Retrieved from https://danishpatentandregistration.dk/publication.aspx
